Nektar Therapeutics (NKTR) Stock Price & Analysis

NKTR$37.27+0.02 +0.05%
Biotechnology
Compare
Market cap$1.07BEnterprise value$1.11BRevenue (TTM)$52.19MMarket position—

Score

45
Neutral
Value
59
Quality
27
Growth
50

AI Analysis

Snapshot

Nektar Therapeutics doesn’t screen as a clean setup today — Stocklytics 45/100 leaves more to prove. Under the hood: revenue compounding ~-12% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

59
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

50
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

27
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Nektar Therapeutics (NKTR) last printed $37.27. Equity value is $1.07B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$165.44M$307.71M$1.19B$114.62M$152.91M$101.91M$92.06M$90.12M$98.43M$55.23M

About

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Nektar Therapeutics (NKTR) Stock Price & Analysis

NKTR price $37.27 +0.02 +0.05%

Ticker
NKTR
Price
$37.27
Change
+0.02 +0.05%
Market cap
$1.07B
Dividend yield
0.00%
Beta
1.15
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
45
Value
59
Quality
27
Growth
50

Stocklytics score rationale: value 59, quality 27, growth 50.

Fair value

NKTR fair value $1,612.05. Price $37.27. Price is 98% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value is the earnings value from next-twelve-months EPS times 28.4, a blend of the industry median and the stock's own 10-year median. A cash-flow value is not available for this stock. How we calculate it →

Model uncertainty high for this stock

Compare NKTR

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-03-02—-2.76—10.47M
2026-11-12-1.63-2.079.39M10.27M
2026-08-13-1.23-1.9710.13M10.43M
2026-05-07-1.82-1.5810.86M10.69M
2026-03-12-1.78-2.4721.81M10.19M
2025-11-06-1.85-2.8511.79M10.05M
2025-08-07-2.95-3.0311.18M9.49M
2025-05-08-3.60-2.5610.46M15.35M
2025-03-120.45-0.1829.18M35.50M
2024-11-07-2.70-2.9924.12M19.18M
2024-08-08-3.75-0.2023.49M18.20M
2024-05-09-2.70-0.1921.64M15.34M
2024-03-04-3.30-0.2123.89M21.43M
2023-11-07-2.85-0.2124.14M21.26M
2023-08-08-4.05-0.2820.50M21.79M
2023-05-09-3.75-0.2521.59M19.41M
2023-02-28-0.32-0.4522.02M22.14M
2022-11-03-3.60-0.4523.62M22.61M
2022-08-04-12.74-14.5521.59M22.62M
2022-05-05-7.35-0.6824.82M24.30M
2022-02-28-0.79-12.0525.01M34.26M
2021-11-04-10.49-11.9924.92M27.82M
2021-08-05-10.34-10.7928.33M25.98M
2021-05-06-10.19-10.7923.65M27.19M
2021-02-25-9.75-10.7923.46M33.58M
2020-11-05-9.15-11.9930.03M36.43M
2020-08-06-6.75-10.3448.85M73.81M
2020-05-07-7.95-12.1450.57M49.92M
2020-02-27-9.60-0.6833.86M35.98M
2019-11-06-8.40-0.7329.22M38.09M
2019-08-08-9.45-0.8023.32M29.61M
2019-05-08-10.19-0.6928.22M28.64M
2019-02-28-8.55-10.4939.83M45.42M
2018-11-07-8.40-9.6027.76M31.23M
2018-08-080.800.801.09B1.07B
2018-05-10-9.00-7.8038.02M34.20M
2018-03-01-2.10-5.7095.47M159.17M
2017-11-075.553.15152.93M106.45M
2017-08-08-5.85-0.3634.59M31.94M
2017-05-09-6.30-0.4224.73M24.70M

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-23WHITFIELD ROY ABuy2.00K——
2026-09-23WHITFIELD ROY ABuy4.00K$57.66230.64K
2026-09-23GREER R SCOTTBuy2.00K——
2026-09-23GREER R SCOTTBuy4.00K$57.66230.64K
2026-09-23CHESS ROBERTBuy2.00K——
2026-09-23CHESS ROBERTBuy4.00K$57.66230.64K
2026-09-23Brainard DianaBuy4.00K$57.66230.64K
2026-09-23Brainard DianaBuy2.00K——
2026-09-23Ajer Jeffrey RobertBuy2.00K——
2026-09-23Ajer Jeffrey RobertBuy4.00K$57.66230.64K
2026-08-18Zalevsky JonathanSell186$71.9813.39K
2026-08-18ROBIN HOWARD WSell418$71.9830.09K
2026-07-24Zalevsky JonathanBuy16.50K$15.15249.97K
2026-07-24ROBIN HOWARD WBuy57.20K$15.15866.58K
2026-06-30Zalevsky JonathanSell5.68K$70.00397.67K
2026-06-17ROBIN HOWARD WSell5.50K$60.81334.45K
2026-06-17ROBIN HOWARD WSell4.50K$61.65277.43K
2026-06-16ROBIN HOWARD WSell5.30K$59.97318.02K
2026-06-16ROBIN HOWARD WSell4.70K$60.71285.15K
2026-06-15Zalevsky JonathanSell5.54K$60.71336.21K
2026-05-19Zalevsky JonathanSell199$65.5113.04K
2026-05-19ROBIN HOWARD WSell444$65.5129.09K
2026-05-15Rubinstein Linda MOther0——
2026-02-18Zalevsky JonathanSell180$73.0013.14K
2026-02-18ROBIN HOWARD WSell423$73.0030.88K
2026-01-20Zalevsky JonathanSell3.87K$35.67137.94K
2025-12-22Zalevsky JonathanBuy6.25K——
2025-12-22Zalevsky JonathanBuy25.00K$43.481.09M
2025-12-22ROBIN HOWARD WBuy86.67K$43.483.77M
2025-12-22ROBIN HOWARD WBuy21.67K——
2025-11-25Zalevsky JonathanSell1.16K$54.2862.80K
2025-11-25Wilson Mark AndrewSell630$54.2834.20K
2025-11-25ROBIN HOWARD WSell2.21K$54.28119.80K
2025-11-21Zalevsky JonathanBuy2.67K——
2025-11-21Zalevsky JonathanBuy4.77K$281.251.34M
2025-11-21Wilson Mark AndrewBuy1.90K——
2025-11-21Wilson Mark AndrewBuy3.40K$281.25956.25K
2025-11-21ROBIN HOWARD WBuy7.11K——
2025-11-21ROBIN HOWARD WBuy12.17K$281.253.42M
2025-09-30WHITFIELD ROY ABuy8.00K$56.90455.20K
2025-09-30GREER R SCOTTBuy8.00K$56.90455.20K
2025-09-30CHESS ROBERTBuy8.00K$56.90455.20K
2025-09-30Brainard DianaBuy8.00K$56.90455.20K
2025-09-30Ajer Jeffrey RobertBuy8.00K$56.90455.20K
2025-09-09ROBIN HOWARD WSell2.10K$45.1694.84K
2025-09-09ROBIN HOWARD WSell1.20K$46.4155.69K
2025-09-09ROBIN HOWARD WSell2.16K$47.49102.39K
2025-09-09ROBIN HOWARD WSell1.21K$48.1858.30K
2025-09-05ROBIN HOWARD WSell3.30K$37.87125.12K
2025-09-05ROBIN HOWARD WSell2.23K$38.8286.41K
2025-09-05ROBIN HOWARD WSell1.14K$39.8945.32K
2025-09-04Zalevsky JonathanSell793$32.4325.72K
2025-09-04Zalevsky JonathanSell432$33.6014.52K
2025-09-04Zalevsky JonathanSell189$34.416.50K
2025-09-04Zalevsky JonathanSell307$35.6910.96K
2025-09-04ROBIN HOWARD WSell1.92K$32.3762.25K
2025-09-04ROBIN HOWARD WSell1.50K$33.5450.18K
2025-09-04ROBIN HOWARD WSell613$34.4021.09K
2025-09-04ROBIN HOWARD WSell1.13K$35.8040.60K
2025-09-02Zalevsky JonathanSell485$30.1014.60K
2025-09-02ROBIN HOWARD WSell1.50K$30.1645.24K
2025-08-19Zalevsky JonathanSell725$26.5919.28K
2025-08-19Zalevsky JonathanBuy16.67K$0.508.33K
2025-08-19Wilson Mark AndrewBuy21.67K$0.5010.83K
2025-08-19Wilson Mark AndrewSell676$26.5917.97K
2025-08-19ROBIN HOWARD WBuy86.67K$0.5043.33K
2025-08-19ROBIN HOWARD WSell1.57K$26.5941.83K
2025-05-19Zalevsky JonathanSell10.71K$0.677.18K
2025-05-19Wilson Mark AndrewSell10.00K$0.676.70K
2025-05-19ROBIN HOWARD WSell23.21K$0.6715.55K
2025-02-19Zalevsky JonathanSell10.30K$1.0110.40K
2025-02-19Wilson Mark AndrewSell11.04K$1.0111.15K
2025-02-19ROBIN HOWARD WSell23.77K$1.0124.01K
2024-12-24Wilson Mark AndrewSell16.56K$0.8914.74K
2024-12-23Wilson Mark AndrewSell33.40K$0.9030.06K
2024-12-19Zalevsky JonathanSell51.12K$0.9448.05K
2024-12-18ROBIN HOWARD WSell85.03K$0.9984.18K
2024-12-17ROBIN HOWARD WSell46.99K$1.0147.46K
2024-12-13Zalevsky JonathanBuy135.00K——
2024-12-13Zalevsky JonathanBuy375.00K$1.01378.75K
2024-12-13Zalevsky JonathanBuy270.00K$4.911.33M
2024-12-13Wilson Mark AndrewBuy165.94K——
2024-12-13Wilson Mark AndrewBuy331.88K$4.911.63M
2024-12-13Wilson Mark AndrewBuy325.00K$1.01328.25K
2024-12-13ROBIN HOWARD WBuy1.30M$1.011.31M
2024-12-13ROBIN HOWARD WBuy410.62K——
2024-12-13ROBIN HOWARD WBuy821.25K$4.914.03M
2024-11-19Zalevsky JonathanSell7.79K$1.017.86K
2024-11-19Wilson Mark AndrewSell6.41K$1.016.47K
2024-11-19ROBIN HOWARD WSell16.28K$1.0116.44K
2024-09-18WHITFIELD ROY ABuy120.00K$1.26151.20K
2024-09-18GREER R SCOTTBuy120.00K$1.26151.20K
2024-09-18CHESS ROBERTBuy120.00K$1.26151.20K
2024-09-18Brainard DianaBuy120.00K$1.26151.20K
2024-09-18Ajer Jeffrey RobertBuy120.00K$1.26151.20K
2024-08-19Zalevsky JonathanSell6.87K$1.288.79K
2024-08-19Wilson Mark AndrewSell5.65K$1.287.23K
2024-08-19ROBIN HOWARD WSell14.88K$1.2819.05K
2024-06-14CHESS ROBERTSell19.50K$1.2023.40K
2024-05-17ROBIN HOWARD WSell16.65K$1.7529.14K

Institutional holders

Latest filed quarter: Q3 2026.

Institutions holding: 171, holders -90 vs prior quarter. Ownership 70.98%.

HolderSharesChangeChange %Value
FMR LLC5.12M53.52K+1.06%310.08M
TWO SEAS CAPITAL LP3.35M253.74K+8.21%202.58M
BLACKROCK, INC.2.87M-70.39K-2.39%173.85M
STATE STREET CORP1.77M862.62K+94.83%107.30M
VANGUARD CAPITAL MANAGEMENT LLC1.50M4.76K+0.32%90.91M
GEODE CAPITAL MANAGEMENT, LLC891.93K10.62K+1.21%54.01M
MORGAN STANLEY830.21K-106.35K-11.36%50.27M
PROSIGHT MANAGEMENT, LP785.00K-25.00K-3.09%47.53M
EMERALD ADVISERS, LLC380.03K-10.13K-2.60%23.01M
VANGUARD PORTFOLIO MANAGEMENT LLC369.52K20.98K+6.02%22.37M
CREEK DRIVE MANAGEMENT GROUP LLC317.00K74.00K+30.45%19.19M
BARCLAYS PLC292.69K30.33K+11.56%17.72M
22NW, LP281.12K00.00%17.02M
CITIGROUP INC280.82K280.82KNew17.00M
PRIMECAP MANAGEMENT CO/CA/272.39K-460-0.17%16.49M
UBS GROUP AG265.87K-162.53K-37.94%16.10M
VANGUARD FIDUCIARY TRUST CO241.89K2.31K+0.97%14.65M
EMERALD MUTUAL FUND ADVISERS TRUST237.45K-18.14K-7.10%14.38M
BRONTE CAPITAL MANAGEMENT PTY LTD.202.06K3.62K+1.83%12.23M
LORD, ABBETT & CO. LLC148.47K-233.16K-61.10%8.99M
QUINN OPPORTUNITY PARTNERS LLC123.08K123.08KNew7.45M
NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A.121.33K121.33KNew7.35M
JANE STREET GROUP, LLC117.70K117.70KNew7.13M
STONEPINE CAPITAL MANAGEMENT, LLC110.00K110.00KNew6.66M
INVESCO LTD.109.22K109.22KNew6.61M

Insights · Forecast · Financials · Learn

Stocklytics home · Screener